Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society
- DOI
- 10.1186/s12961-025-01421-w
- Published
- 2025-11-28
- Container
- Health Research Policy and Systems
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12961-025-01421-w,
title = {Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society},
author = {Anna Wong and Gul Saeed and Sarah Garner and Jillian Kohler},
year = {2025},
journal = {Health Research Policy and Systems},
doi = {10.1186/s12961-025-01421-w},
url = {https://doi.org/10.1186/s12961-025-01421-w}
}RIS
TY - JOUR TI - Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society AU - Anna Wong AU - Gul Saeed AU - Sarah Garner AU - Jillian Kohler PY - 2025 JO - Health Research Policy and Systems DO - 10.1186/s12961-025-01421-w UR - https://doi.org/10.1186/s12961-025-01421-w ER -
APA
Wong, A., Saeed, G., Garner, S., & Kohler, J. (2025). Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society. Health Research Policy and Systems. https://doi.org/10.1186/s12961-025-01421-w
Source records
- crossref · retrieved 2026-11-10T18:54:20.273Z